Search the Newsreel

Airsculpt Technologies Inc (AIRS) Stock News Today

Federal Agricultural Mortgage (AGM) Could Be 59% Overvalued As Strong Earnings Lift Sentiment

4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview

4D Molecular Therapeutics Inc (FDMT) is projected to report a loss of $1.02 per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article provides a brief outlook on the company's expected financial performance.

Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM

Renaissance Technologies LLC has reduced its stake in Cullinan Therapeutics (NASDAQ:CGEM) by 48.7% during the first quarter, selling 307,595 shares and retaining 324,111 shares valued at $4.6 million. Despite this sale, institutional investors collectively hold 86.31% of the company's stock, and analysts maintain a …

Culp Inc (CULP) VP reports holding 4,334 common shares

Dekon Food and Agriculture Group Sets August Board Meeting for Interim Results

Agriculture & Natural Solutions Acquisition Corp (ANSC) Stock News Today

Cullen/Frost Bankers Inc (CFR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cullen/Frost Bankers Inc (CFR), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 15 analysts, the stock has a "Hold" rating, with an expected revenue of $609.37M for the next quarter and …

MOLN Q4 2025 Earnings: Loss Narrower Than Expected Amid Continuing Development Focus - Full Year Guidance

Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results

Oculis Holding earnings beat by CHF0.23, revenue topped estimates

Oculis Holding reported second-quarter earnings that surpassed analyst estimates by CHF0.23, with revenue also exceeding expectations at CHF311.14K against a consensus of CHF157.82K. Despite the positive earnings surprise, the company's stock price has seen a significant decline, down -62.070% in the last 3 months …

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) reported a narrower-than-expected Q2 loss of $0.2 per share, beating the Zacks Consensus Estimate of a $0.48 loss, and surpassed revenue estimates with $0.39 million. Despite this, the company's shares have fallen 39.6% year-to-date, contrasting with the S&P 500's gain, …

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Cullinan Therapeutics announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its immunology and oncology pipeline. The company reported promising clinical data for CLN-978 and velinotamig in autoimmune diseases, with Phase 2 studies anticipated to begin in early 2027. …

Hercules Capital, Inc. (NYSE:HTGC) Given Average Recommendation of "Moderate Buy" by Analysts

Analysts have issued a "Moderate Buy" consensus rating for Hercules Capital, Inc. (NYSE:HTGC), with an average 12-month price target of $18.46, surpassing its current share price of $16.73. The company recently reported quarterly earnings of $0.50 per share, exceeding estimates, and increased its quarterly …

4D Molecular Therapeutics, Inc. (FDMT) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial information for 4D Molecular Therapeutics, Inc. (FDMT), a late-stage biotechnology company. It includes real-time stock price, historical data, performance metrics against the S&P 500, analyst ratings,

LeMaitre management to meet investors at virtual Aug. 11 event

LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its management will participate in investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026. The event will be held in a virtual format. The company specializes in devices …

Moleculin Biotech (MBRX) stake capped at 4.99% under Intracoastal warrants

A Schedule 13G filing indicates that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively hold a beneficial ownership of 4.99% in Moleculin Biotech, Inc. (MBRX), amounting to 973,927 shares. This ownership includes shares held directly by Intracoastal and shares issuable upon …

Oculis birtir uppgjör fyrir annan ársfjórðung 2026 og kynnir áfanga í rekstri félagsins

ZUG, Sviss, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Félagið færir nú áherslur sínar yfir á taugaauknlækningar með Privosegtor sem leiðandi þróunarlyf félagsins á síðari stigum klínískrar þróunar í gegnum PIONEER-áætlunina. Í kjölfar jákvæðs pre-IND fundar við Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA), eru möguleikar á …

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Oculis, a global biopharmaceutical company, announced its Q2 2026 financial results, reporting $282.3 million in cash, cash equivalents, and short-term investments, providing a cash runway into the second half of 2029. The company is advancing its neuro-ophthalmology pivot with Privosegtor as a lead late-stage …

Moleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrants

Moleculin Biotech, Inc.'s CFO, Jonathan P. Foster, recently purchased 293,333 shares of common stock and 879,999 Series I Warrants in a public offering. These were acquired at a combined price of $0.75 per unit, with each unit comprising one share and three warrants. Following …

Federal Agricultural Mortgage Corporation (AGM-A) stock price, news, quote and history

Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history

This article provides a detailed overview of Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company focused on autoimmune diseases and cancer. It includes current stock price, historical data, financial metrics, analyst ratings, and a company profile highlighting its drug development pipeline. The company's stock …

LeMaitre Vascular To Go Ex-Dividend On August 20th, 2026 With 0.25 USD Dividend Per Share

LeMaitre Vascular is scheduled to go ex-dividend on August 20th, 2026. The company will be distributing a dividend of $0.25 per share to its shareholders. Investors wishing to receive this dividend should ensure they own shares before the ex-dividend date.

LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

LeMaitre Vascular, Inc. announced its participation in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026, where management will hold investor meetings. The company, a provider of devices for peripheral vascular disease, aims to connect with investors regarding its …

Moleculin Biotech, Inc. (MBRX) CEO adds stock and 1.6M Series I warrants

Moleculin Biotech, Inc.'s CEO, Walter V. Klemp, reported acquiring 533,333 shares of common stock and 1,599,999 Series I warrants in a public offering on August 3, 2026. The purchase was made at a combined price of $0.75 per common share and three accompanying warrants. …

Are You Looking for a Top Momentum Pick? Why Cullen/Frost Bankers (CFR) is a Great Choice

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

LeMaitre Vascular (LMAT) Hit by Profit Taking

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

Here's What Analysts Are Forecasting For Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Second-Quarter Results

Ocular Therapeutix (NASDAQ:OCUL) recently released strong second-quarter results, beating revenue expectations and posting smaller-than-anticipated statutory losses. Analysts have slightly increased their optimism regarding per-share losses for 2026, though revenue forecasts remain unchanged. Despite this, the consensus price target of US$27.09 has not shifted, and …

Cullinan to begin potentially registrational acute myeloid leukemia study in Q3

Cullinan Therapeutics reported a Q2 2026 net loss of $53.7 million but maintained a strong cash position of $356 million, providing a runway into 2029. The company announced several upcoming clinical milestones for its immunology and oncology pipeline, including the initiation of a potentially …

LeMaitre Vascular (LMAT) Stock Price Hit By Revenue Guidance Cut

W. R. Berkley (ANSC) discloses 3.27M-share, 9.9% holding in SPAC

W. R. Berkley Corporation, through its subsidiary Berkley Insurance Company, has disclosed a 9.9% beneficial ownership in Agriculture & Natural Solutions Acquisition Corporation (ANSC), a SPAC. This holding amounts to 3,265,181 Class A ordinary shares as of June 30, 2026. The filing indicates shared …

Insight Molecular Diagnostics (IMDX) Slides 3.6% to $4.82: Support Test in Focus - Volatility Smirk

Hercules Capital: 0.1% Non-Accruals, 125% Coverage, Top BDC Value (NYSE:HTGC)

Hercules Capital 6.25% Notes Due 2033 (HCXY) Hold Steady at $25.07 in Quiet Session - Protective Put

HC Wainwright Has Negative Estimate for OCUL Q3 Earnings

Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates